Physician profile
Manoj Vasant Waikar
NPI 1821150574
$1,890,799.53
in general payments reported to CMS, 2019-2025
24 companies · $413K in 2025
The $413K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200K · 2020: $145K · 2021: $183K · 2022: $297K · 2023: $353K · 2024: $300K · 2025: $413K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $717K · Travel and Lodging: $210K · Consulting Fee: $62K · Honoraria: $45K · Food and Beverage: $32K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $717,019.40 |
| Travel and Lodging | $210,052.53 |
| Consulting Fee | $61,954.70 |
| Honoraria | $45,225.00 |
| Food and Beverage | $31,693.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $721,504.32 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $355,602.75 | 2020-2025 | Caplyta |
| Abbvie INC. | $286,977.50 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $170,561.89 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $104,084.87 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $83,082.00 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $74,182.55 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $47,566.90 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $30,791.15 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $8,410.76 | 2019-2023 | Rexulti |
| Luye Pharma (USA) Ltd. | $4,664.37 | 2025 | Erzofri Extended-Release |
| Acadia Pharmaceuticals INC | $1,551.95 | 2019-2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $463.50 | 2019-2021 | |
| Eisai INC. | $410.55 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $392.56 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $192.20 | 2022-2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $124.26 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $100.32 | 2022-2023 | Quviviq |
| Resmed Corp | $26.73 | 2022 | |
| Merck Sharp & Dohme LLC | $25.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $24.31 | 2021 | |
| Indivior INC. | $22.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.08 | 2022 | |
| Lundbeck LLC | $17.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Waikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.